Verastem (VSTM) Retained Earnings (2011 - 2026)
Verastem (VSTM) posted quarterly Retained Earnings of -$1.2 billion for Q1 2026, down 19.25% year-over-year from -$1.5 billion in Q1 2025, and down 3.14% quarter-over-quarter from -$1.2 billion in Q4 2025.
Analysis
Verastem (VSTM) Retained Earnings (2011 - 2026) Analysis & Trends
Verastem's Retained Earnings history runs 16 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 19.25% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 19.25% YoY), while the FY2025 annual figure was -$1.2 billion, down 21.92% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1.2 billion, down from -$1.2 billion in the prior quarter.
- The five-year high for Retained Earnings was -$4000.0 in Q1 2024, with the low at -$1.2 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$824.9 million (2023), against an average of -$838.1 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 100.0% in 2024, then slumped 25190650.0% in 2025.
- Verastem's Retained Earnings stood at -$737.5 million in 2022, then decreased by 11.85% to -$824.9 million in 2023, then fell by 15.84% to -$955.5 million in 2024, then slipped by 21.92% to -$1.2 billion in 2025, then decreased by 3.14% to -$1.2 billion in 2026.
- Business Quant data shows VSTM's Retained Earnings at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -1.24 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.24 Bn |
| Mar 31, 2026 | -1.20 Bn |
| Dec 31, 2025 | -1.16 Bn |
| Sep 30, 2025 | -1.13 Bn |
| Jun 30, 2025 | -1.03 Bn |
| Mar 31, 2025 | -1.01 Bn |
| Dec 31, 2024 | -955.53 Mn |
| Sep 30, 2024 | -890.98 Mn |
| Jun 30, 2024 | -867.01 Mn |
| Mar 31, 2024 | -858.75 Mn |
| Dec 31, 2023 | -824.89 Mn |
| Sep 30, 2023 | -797.52 Mn |
| Jun 30, 2023 | -777.52 Mn |
| Mar 31, 2023 | -753.24 Mn |
| Dec 31, 2022 | -737.52 Mn |
| Sep 30, 2022 | -720.72 Mn |
| Jun 30, 2022 | -702.63 Mn |
| Mar 31, 2022 | -680.70 Mn |
| Dec 31, 2021 | -663.71 Mn |
| Sep 30, 2021 | -647.23 Mn |